Clinical Trials Logo
  1. Home
  2. Chronic Granulomatous Disease
  3. NCT03548818

Role of Interferon-gamma 1-b (IFN-γ) on Cells of the Innate Immune System: Functional, Biochemical and Gene Expression Studies in Patients With Chronic Granulomatous Disease

Chronic Granulomatous Disease Clinical Trial

Official title:
Role of Interferon-gamma 1-b (IFN-γ) on Cells of the Innate Immune System: Functional, Biochemical and Gene Expression Studies in Patients With Chronic Granulomatous Disease

Clinical Trial Summary

The overall goal of the study is to investigate the functional, biochemical, and gene expression effects of Interferon-gamma 1-b (IFN-γ) on the neutrophils of patients with Chronic Granulomatous Disease (CGD). The investigators hypothesize that the clinical effects demonstrated in patients with CGD treated with IFN-γ (decreased number and severity of infections) are the result of biochemical processes and upregulation of specific genes, which lead to enhanced functionality of this immune cell population.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03548818
Study type Observational
Source University of Colorado, Denver
Contact
Status Completed
Phase
Start date May 16, 2018
Completion date July 15, 2020
View Details
See also
  Status Clinical Trial Phase
Withdrawn NCT03278912 - Natural History of Intestinal Inflammation in People With Primary Immune Dysregulations
Recruiting NCT01652092 - Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies N/A
Completed NCT04136028 - IL-1 Receptor Inhibitor for Granulomatous Complications in Patients With Chronic Granulomatous Disease Early Phase 1
Recruiting NCT05687474 - Baby Detect : Genomic Newborn Screening
Terminated NCT03080480 - Pioglitazone Therapy for Chronic Granulomatous Disease Phase 1/Phase 2
Terminated NCT00394316 - Gene Therapy for Chronic Granulomatous Disease Early Phase 1
Recruiting NCT03910452 - Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide Early Phase 1
Terminated NCT02282904 - Haploidentical Transplant for People With Chronic Granulomatous Disease Using Post Transplant Cyclophosphamide Phase 1/Phase 2
Terminated NCT02926963 - Generation of Powerful Biological Tools for Understanding the Pathophysiology of Chronic Granulomatous Disease. N/A
Completed NCT00006417 - Modified Stem Cell Transplantation Procedure for Treating Chronic Granulomatous Disease Phase 2
Completed NCT00368446 - Genetic Disorders of Mucociliary Clearance in Nontuberculous Mycobacterial Lung Disease
Enrolling by invitation NCT03655223 - Early Check: Expanded Screening in Newborns
Recruiting NCT06162936 - Neutrophil Oxidative Burst in Early and Late Onset Pediatric Inflammatory Bowel Disease
Enrolling by invitation NCT06253507 - pCCLCHIM-p47 (Lentiviral Vector Transduced CD34 Plus Cells) in Patients With p47 Autosomal Recessive Chronic Granulomatous Disease (AR-CGD) Phase 1/Phase 2
Terminated NCT05915897 - Whole Blood Biospecimen Collection for Subjects With Chronic Granulomatous Disease (CGD)
Terminated NCT00325078 - Infliximab to Treat Crohn'S-like Inflammatory Bowel Disease in Chronic Granulomatous Disease Phase 1/Phase 2
Completed NCT00001317 - A Phase IV Study of Recombinant Human Gamma Interferon in Patients With Chronic Granulomatous Diseases of Childhood Phase 4
Recruiting NCT01821781 - Immune Disorder HSCT Protocol Phase 2
Completed NCT00578643 - Matched Unrelated or Non-Genotype Identical Related Donor Transplantation For Chronic Granulomatous Disease Phase 2
Terminated NCT00006054 - Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies N/A